3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NIH
2
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Non-Small-Cell Lung
2
Ulcer
1
Stomatitis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Burkitt Lymphoma
1
Adenocarcinoma
1
Interventions
Cytarabine
21
Imatinib Mesylate
20
venetoclax
16
Azacitidine
16
nilotinib
15
Cyclophosphamide
15
fludarabine
13
Dasatinib
12
blinatumomab
10
Rituximab
10
quizartinib
7
Gemtuzumab
7
Daunorubicin
7
ruxolitinib
6
Drug Therapy
6
Clofarabine
6
Bendamustine Hydrochloride
6
AP 1903 reagent
6
ponatinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vincristine
5
Mycophenolic Acid
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Dexamethasone
5
vosaroxin
4
revumenib
4
rasburicase
4
forodesine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia
×
Acetaminophen
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts